Victor A Levin
Overview
Explore the profile of Victor A Levin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westphal M, Levin V, Berger M, Pieper R, Nishikawa R, Bjerkvig R, et al.
J Neurosurg
. 2024 Dec;
142(3):892-898.
PMID: 39705690
No abstract available.
2.
Ellingson B, Levin V, Cloughesy T
Neurotherapeutics
. 2022 Apr;
19(6):1855-1868.
PMID: 35451676
There is an urgent need for drug development in brain tumors. While current radiographic response assessment provides instructions for identifying large treatment effects in simple high- and low-grade gliomas, there...
3.
Chen H, Kuhn J, Lamborn K, Abrey L, DeAngelis L, Lieberman F, et al.
Neurooncol Adv
. 2020 Nov;
2(1):vdaa124.
PMID: 33235994
Background: Receptor tyrosine kinases such as epidermal growth factor receptors (EGFRs) and their downstream signaling pathways such as the Ras-Raf-mitogen-activated protein kinase (MAPK) pathway play important roles in glioblastoma (GBM)....
4.
Yam N, Levin J, Bao Z, Qian W, Levin V
Oncotarget
. 2020 Nov;
11(44):3933-3942.
PMID: 33216820
Treatment of infiltrative glioma presents a number of unique challenges due to poor penetration of typical chemotherapeutic agents into the infiltrating edge of tumors. The current chemotherapy options include nitrosoureas...
5.
6.
7.
Levin V, Ellingson B
Neuro Oncol
. 2018 Feb;
20(5):589-596.
PMID: 29474640
This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the...
8.
Levin V, Ictech S, Hess K
CNS Oncol
. 2018 Jan;
7(2):CNS16.
PMID: 29378419
This review covers the literature between 1989 and 2007 on studies relevant to the neuro-oncology usage of eflornithine (α-difluoromethylornithine), an oral agent that irreversibly inhibits the enzyme ornithine decarboxylase. It...
9.
Nghiemphu P, Ebiana V, Wen P, Gilbert M, Abrey L, Lieberman F, et al.
J Neurooncol
. 2017 Oct;
136(1):79-86.
PMID: 28988377
Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order...
10.
Levin V, Abrey L, Heffron T, Tonge P, Dar A, Weiss W, et al.
CNS Oncol
. 2017 Jul;
6(3):167-177.
PMID: 28718326
The 2016 second CNS Anticancer Drug Discovery and Development Conference addressed diverse viewpoints about why new drug discovery/development focused on CNS cancers has been sorely lacking. Despite more than 70,000...